Unknown OBSERVATIONAL NCT01696591

The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

Sponsor: Duk Lyul Na

Conditions Alzheimer Disease Brain Diseases Central Nervous System Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Dementia Mental Disorders Nervous System Diseases Neurodegenerative Diseases Tauopathies

Interventions NEUROSTEM®-AD

Updated 7 times since 2017 Last updated: Sep 27, 2012 Started: Mar 31, 2012 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Alzheimer Disease and Brain Diseases, this trial is ongoing. The trial is conducted by Duk Lyul Na and has accumulated 7 data snapshots since 2012. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown
Sep 2024 — Sep 2025 [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duk Lyul Na
Medipost Co Ltd.

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea